Anzeige
+++Ocean Partners steigt bei Grande Portage ein: +48 % in Deutschland! Ocean Partners steigt bei Grande Portage ein +48 % in Deutschland! Ocean Partners steigt bei Grande Portage ein+++
EQS-News

Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis 12.06.2026, 09:35 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Simcere Pharmaceutical Group Limited / Key word(s): Agreement/Contract
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis

12.06.2026 / 09:35 CET/CEST
The issuer is solely responsible for the content of this announcement.


SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF).

According to the agreement, Simcere Pharmaceutical will fund the exploratory research of this first-in-class novel molecule. Upon successful completion, Simcere will in-license the molecule and obtain 100% of the global rights to the resulting product.

The project will be carried out in collaboration with world-class chemical biology laboratories at Stanford Medicine led by Chaitan Khosla, PhD, and Cui Bianxiao, PhD, affiliated with the Stanford Innovative Medicines Accelerator. Khosla is a professor in the Departments of Chemistry and Chemical Engineering at Stanford University, an Institute Scholar of the Sarafan ChEM-H Institute, and Director of the Innovative Medicines Accelerator. He is a member of the U.S. National Academy of Sciences, the National Academy of Engineering, and the American Academy of Arts and Sciences, and an expert in LYTAC-related technologies. Bianxiao is a professor in the Department of Chemistry at Stanford University and a Fellow of the Wu Tsai Neuroscience Institute. She is an expert in fibrosis-related targets. She has received awards including the Biophysical Society's Barany Award and the NIH New Innovator Award.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial pneumonia of unknown etiology, characterized by fibrosis that primarily affects the pulmonary interstitium, leading to stiffening and loss of elasticity of lung tissue, and ultimately resulting in respiratory failure. Current medical treatments cannot completely reverse pulmonary fibrosis; from the time of diagnosis, the median survival time of patients is approximately 3 years, with a 5-year survival rate of only 20–40%.

Mr. Zhou Gaobo, Chief Investment Officer of Simcere Pharmaceutical, stated: "This marks the second first-in-class original project worldwide in collaboration between Simcere and Stanford Medicine. This ongoing collaboration reflects Simcere's active steps toward Innovation 2.0 and fulfills its corporate mission ('For patients, for life'). We look forward to jointly developing more innovative products to benefit patients."

Professor Khosla stated: "Highly targeted therapies for idiopathic pulmonary fibrosis have long been an urgent unmet clinical need. We are pleased to work with Simcere to advance the translation of chemical biology breakthroughs together."

About Simcere Pharmaceutical

Simcere Pharmaceutical (2096.HK) is an innovation and R&D-driven pharmaceutical company, and has established the National Key Laboratory for Neurology and Oncology Drug Development. The company focuses on the fields of neuroscience, oncology, autoimmune, and anti-infection, while proactively planning for disease areas with significant unmet clinical needs, fulfilling its corporate mission of "For patients, for life". Leveraging both independent R&D and collaborative innovation, the company has formed strategic partnerships with numerous innovative companies and research institutions. For more information, please visit: www.simcere.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/simcere-pharmaceutical-enters-into-a-research-collaboration-agreement-with-stanford-medicine-to-develop-innovative-therapies-for-patients-with-idiopathic-pulmonary-fibrosis-302798903.html

rt.gif?NewsItemId=EN82381&Transmission_Id=202606120332PR_NEWS_EURO_ND__EN82381&DateId=20260612


12.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2345060  12.06.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer